Open access
Jul 2026
GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer.
GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets, and was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC.
Jihan Qiu, Cheng Tian, Hanzhi Li et al.
· Frontiers in Bioscience · 0 citations